Disease Markers

Clinical Study

Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy

Table 5

Univariate survival analysis of OS for LACSCC patients with neutropenia.


Clinicopathologic characteristics	⁢OS		value
Clinicopathologic characteristics	Mean ± SD (months)	95% CI	value

Age
≤50 years	45.21 ± 4.54	−21.451–3.589	0.155
>50 years	54.14 ± 3.60	−21.451–3.589	0.155
Histologic grade
Well and moderately differentiated	51.64 ± 4.19	−8.242–17.422	0.471
Poorly differentiated	47.05 ± 4.42	−8.242–17.422	0.471
Tumor size
≤4 cm	47.33 ± 3.90	−20.303–8.075	0.386
>4 cm	53.44 ± 4.40	−20.303–8.075	0.386
Parametrial invasion
No	45.15 ± 3.19	−27.924–13.195	0.420
Unilateral	54.07 ± 2.56
Bilateral	46.71 ± 4.37
Clinical lymph node involvement
cN0	54.50 ± 2.96	−26.016–1.912	0.025
cN1	40.54 ± 5.76	−26.016–1.912	0.025
FIGO stage
II	50.71 ± 3.88	−16.257–9.215	0.057
III	47.19 ± 4.93	−16.257–9.215	0.057
Hemoglobin levels at diagnosis (g/dL)
≤113	47.70 ± 3.95	−9.524–18.138	0.530
>113	52.00 ± 4.73	−9.524–18.138	0.530
Platelets at diagnosis (g/dL)
≤320	49.24 ± 3.27	−17.599–21.580	0.837
>320	47.25 ± 10.49	−17.599–21.580	0.837
Response
CR	44.80 ± 5.15	−20.231–4.832	0.219
Non-CR	52.50 ± 3.60	−20.231–4.832	0.219
RNG
≥3.01	40.06 ± 4.80	7.571–29.312	0.002
<3.01	58.50 ± 2.00	7.571–29.312	0.002

OS, overall survival; LACSCC, locally advanced cervical squamous cell carcinomas; FIGO, International Federation of Gynecology and Obstetrics; CR, complete response; RNG, responses of neutrophil to granulocyte colony-stimulating factors.